Quironsalud Madrid
Acute lymphoblastic leukemia treatment cost in Spain typically starts with a comprehensive diagnosis of leukemia ranging from $1,500 to $3,200. Primary treatment involving allogenic bone marrow transplantation from a related donor runs from $13,900 to $194,100. Total expenses depend on the leukemia subtype, treatment cycles, and patient age. Patients often save between 30-50% compared to US costs. Top treatment centers are located in Barcelona, Madrid, and Pamplona.
Typical Acute Lymphoblastic Leukemia Treatment Costs in Spain
Bookimed Expert Insight: Pediatric patients achieve the best results at specialized centers like SJD Barcelona Children's Hospital. This top-3 European institution features experts like Dr. Jaume Mora Graupera for complex oncology cases. Adult patients requiring advanced hematology care should consider JCI-accredited facilities like Centro Médico Teknon. For those seeking innovative options, Quironsalud Madrid provides unique access to clinical trials and national CAR-T programs. Clinica Universidad de Navarra is ideal for international patients, having treated people from 70 countries.
| Turkey | Austria | Spain | |
| Chemotherapy for breast cancer | from $1,200 | from $15,000 | from $3,500 |
| Bone marrow transplantation | from $36,000 | from $140,000 | from $71,782 |
| Autologous bone marrow transplantation | from $31,500 | from $50,000 | from $40,000 |
| Allogenic bone marrow transplantation from an unrelated donor | from $80,000 | from $180,000 | from $150,000 |
| Allogenic bone marrow transplantation from a related donor | from $65,000 | from $150,000 | from $13,941 |
Specialist in bone marrow transplantation – Susana Rives Sola focuses on pediatric hematology at SJD Barcelona Children's Hospital.
Dr. Graupera is an awarded pediatric oncologist, specializing in bone and soft tissue sarcomas at SJD Barcelona Children's Hospital — one of Europe's top children's hospitals.
Over 1,100 treatments performed in hematology – Dr. Cobo Valien specializes in acute and chronic leukemias at Centro Médico Teknon.
Globally recognized leader in chronic lymphocytic leukemia (CLL) and lymphomas – Dr. Bosch pioneers new treatments and molecular research at Hospital Quiron Barcelona.
Treatment for Acute Lymphoblastic Leukemia in Spain follows three sequential stages: remission induction, consolidation, and maintenance. Spanish protocols like PETHEMA standardize care over 2 to 3 years. Therapy integrates intensive chemotherapy, central nervous system prophylaxis, and molecular tailoring based on residual disease markers.
Bookimed Expert Insight: Spanish centers like SJD Barcelona Children’s Hospital and Quironsalud Madrid focus heavily on Minimal Residual Disease (MRD) monitoring. This data point is vital because it determines if a patient moves to standard maintenance or requires an intensified path. For high-risk cases, surgeons like Dr. Luis Madero may transition patients directly to allogeneic bone marrow transplantation early in the protocol.
Patient Consensus: Patients note that the first induction phase is the most challenging due to fatigue, infection risks, and long hospital stays. They emphasize the importance of asking early if molecular testing will be used to guide the intensity of later treatment phases.
Spain offers leading-edge therapies for relapsed or refractory ALL, prioritizing chimeric antigen receptor (CAR) T-cell treatments. Patients access academic ARI-0001 therapy for adults over 25 and commercial tisagenlecleucel for younger patients. High-volume centers also provide advanced allogeneic bone marrow transplantation from unrelated donors.
Bookimed Expert Insight: Spain’s unique Hospital Exemption pathway creates a bridge for adults often excluded from commercial CAR-T protocols. While many industrial drugs stop at age 25, academic trials at Hospital Clinic Barcelona treat patients through age 80. This makes Spain a primary destination for adult R/R ALL cases globally.
Patient Consensus: Patients often discuss using blinatumomab as a bridge therapy to stabilize their condition before receiving CAR-T or a transplant. They emphasize checking antigen markers early to determine if their leukemia subtype matches these targeted therapies.
Spain leads acute lymphoblastic leukemia (ALL) care through Joint Commission International (JCI)-accredited facilities specializing in advanced CAR T-cell therapies and complex bone marrow transplants. Recognized centers include SJD Barcelona Children's Hospital for pediatric cases and Quironsalud Madrid for adult hematology. These hospitals employ molecular diagnostics and clinical trials.
Bookimed Expert Insight: While many choose famous hospitals in Madrid or Barcelona, Clinica Universidad de Navarra stands out as the first in Spain to receive JCI accreditation. Data shows they have treated over 700,000 international patients. This suggests a deeply established infrastructure for handling complex logistics and second opinions for non-residents. Their focus on risk stratification is ideal for adult ALL patients seeking personalized protocols.
Patient Consensus: Patients emphasize finding major university hospitals with dedicated hematology services and checking for allogeneic stem cell transplant access. Many recommend inquiring about minimal residual disease (MRD) testing to ensure treatment matches modern risk-stratified standards.
Spanish medical centers report overall 5-year survival rates for childhood acute lymphoblastic leukemia between 85% and 90%. Success rates for adult patients vary based on age and genetic profile. These outcomes are supported by access to advanced technologies like CAR-T cell therapy and allogeneic bone marrow transplantation.
Bookimed Expert Insight: Patient volume in Spain is a strong indicator of expertise in complex hematology. Quironsalud Madrid and SJD Barcelona Children's Hospital serve a combined 450,000+ patients annually. This high volume allows specialists like Dr. Luis Madero and Dr. Isabel Badell Serra to refine bone marrow transplant protocols, which are essential for long-term remission in high-risk adult and pediatric cases.
Patient Consensus: Patients emphasize that early response to induction therapy and minimal residual disease results are better predictors of success than general statistics. They note that pediatric cases are highly treatable, while adults prioritize finding centers with high-volume transplant experience.